Evidence Level
Myo-inositol is a well-researched supplement with significant applications in reproductive and metabolic health. The 2017 International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology has endorsed its use, particularly for managing polycystic ovary syndrome (PCOS). Unfer et al. (2012) conducted a comprehensive meta-analysis that demonstrated significant improvements in insulin resistance, androgen levels, and ovulatory function among women with PCOS. The optimal 40:1 ratio of myo-inositol to D-chiro-inositol, as proposed by Nordio & Proietti (2012), aligns with the physiological plasma ratio and has been shown to yield better outcomes than using either isomer alone.
Recent studies further support its benefits across various conditions. Zhang et al. (2025) found that myo-inositol supplementation improves MII oocyte and fertilization rates in IVF, particularly for women with PCOS. Conversely, Pivazyan et al. (2025) reported no significant benefits of myo-inositol on oocyte/embryo quality or pregnancy outcomes in assisted reproduction. In the context of thyroid disorders, Yavari et al. (2024) demonstrated that combined selenium and myo-inositol supplements significantly increased T4 levels and decreased TSH but did not affect T3 or TPOAb levels.
For gestational diabetes prevention, Factor & Corpuz (2023) found that 4g of myo-inositol daily may reduce the risk. Chen et al. (2024) further corroborated these findings in a meta-analysis involving women with gestational diabetes. Overall, myo-inositol's role extends beyond PCOS to other metabolic and reproductive conditions, supported by robust evidence from multiple studies.